Posts Tagged ‘royalties’

Why the market does not like Flurizan

Guest content from Nicolaj H. Nielsen, managing director of Biostrat. A case-study on the recent licensing-deal between Myriad and Lundbeck: Information asymmetry, calculated bets and royalties in the biotech industry. The share-price of Lundbeck has fallen with approximately 10 %, since the Danish pharmaceutical company announced an inlicensing deal with the US biotech company Myriad […]